Routine interferon-neutralising antibody testing in patients with relapsing-remitting multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Multiple sclerosis (MS) is a significant cause of disability in young adults.
• Scotland has the highest prevalence of MS in Europe.
• Beta-interferon (IFN-ß) is a common disease-modifying therapy for relapsing-remitting MS.

Purpose of the Study:

• To evaluate the implementation and implications of routine neutralising antibody (NAB) testing for IFN-ß in MS patients.
• To assess the prevalence of NABs in a Scottish MS population.
• To comment on the cost-effectiveness and clinical utility of routine NAB testing.

Main Methods:

• Serum samples were collected from 105 patients over two years in NHS Tayside.
• NAB testing was performed to detect antibodies against IFN-ß.
• Data on NAB positivity and its implications were analyzed.

Main Results:

• 35 out of 105 patients (33.3%) tested positive for NABs.
• Routine testing provided data on antibody prevalence within the study cohort.
• The study discusses the cost and broader implications of implementing routine NAB testing.

Conclusions:

• Routine NAB testing for IFN-ß in MS patients is a viable strategy.
• Understanding NAB prevalence is crucial for optimizing MS treatment efficacy.
• Further evaluation is needed to establish universal protocols for NAB testing in MS management.